{
    "clinical_study": {
        "@rank": "127798", 
        "acronym": "IMPROVE", 
        "arm_group": [
            {
                "arm_group_label": "IV morphine sulfate", 
                "arm_group_type": "Active Comparator", 
                "description": "morphine sulfate"
            }, 
            {
                "arm_group_label": "EXPAREL", 
                "arm_group_type": "Experimental", 
                "description": "EXPAREL (bupivacaine liposome injectable suspension)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome\n      injectable suspension) to determine if total opioid consumption is reduced when using\n      EXPAREL, thereby possibly reducing total hospitalization costs."
        }, 
        "brief_title": "A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy: IMPROVE - Lap Colectomy", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Bowel Obstruction", 
        "condition_browse": {
            "mesh_term": "Intestinal Obstruction"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 4 prospective, sequential, open-label study designed to evaluate the\n      efficacy, safety, and health economic benefits of intraoperative local wound infiltration\n      with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical\n      administration of standardized intravenous (IV) morphine sulfate for postsurgical analgesia\n      in adult patients undergoing laparoscopic colectomy with general anesthesia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 years of age and older.\n\n          -  Patients scheduled to undergo laparoscopic-assisted colectomy with planned primary\n             anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse\n             colon, left hemicolectomy, or sigmoidectomy. (Note: patients who convert from a\n             planned laparoscopic colectomy to an open colectomy are not eligible)\n\n          -  Ability to provide informed consent, adhere to study visit schedule, and complete all\n             assessments.\n\n        Exclusion Criteria:\n\n          -  Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance\n             to any local anesthetic, opioid, or propofol.\n\n          -  Patients who abuse alcohol or other drug substance.\n\n          -  Patients with severe hepatic impairment.\n\n          -  Patients currently pregnant or who may become pregnant during the course of the\n             study.\n\n          -  Patients with any psychiatric, psychological, or other condition that the\n             Investigator feels may make the patient an inappropriate candidate for this clinical\n             study.\n\n          -  Patients who have participated in an EXPAREL study within the last 30 days.\n\n          -  Patients who have received an investigational drug within 30 days prior to study drug\n             administration, or planned administration of another investigational product or\n             procedure during the patient's participation in this study.\n\n        In addition, the patient will be ineligible if he/she meets the following criteria during\n        surgery:\n\n          -  Patients who have any concurrent surgical procedure.\n\n          -  Patients with unplanned multiple segmental resections or large intestine.\n\n          -  Patients who convert from laparoscopic-assisted colectomy to traditional open\n             colectomy.\n\n          -  Patients who have unplanned, temporary, or permanent colostomies placed.\n\n          -  Patients who receive intraoperative administration of opioids (other than fentanyl or\n             analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.\n\n          -  Patients who receive Entereg(R)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963975", 
            "org_study_id": "MA402S23B609"
        }, 
        "intervention": [
            {
                "arm_group_label": "IV morphine sulfate", 
                "description": "Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed.  The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than one hour.", 
                "intervention_name": "IV Morphine Sulfate", 
                "intervention_type": "Drug", 
                "other_name": "Morphine"
            }, 
            {
                "arm_group_label": "EXPAREL", 
                "description": "Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure.  When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery.  If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.\nAll patients will be offered rescue analgesia, as needed.", 
                "intervention_name": "EXPAREL", 
                "intervention_type": "Drug", 
                "other_name": "Bupivacaine liposome injectable suspension"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bupivacaine", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Colectomy", 
            "Laparoscopic colectomy"
        ], 
        "lastchanged_date": "October 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington DC", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20010"
                }, 
                "name": "Washington Hospital Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)", 
        "overall_official": {
            "affiliation": "Washington Hospital Center", 
            "last_name": "Anjali Kumar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written through Day 30, whichever is sooner.", 
                "measure": "Total opioid burden", 
                "safety_issue": "Yes", 
                "time_frame": "Wound closure to time hospital discharge order is written or Day 30, whichever is sooner"
            }, 
            {
                "description": "Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner.", 
                "measure": "Health economic benefits: Total cost of hospitalization", 
                "safety_issue": "No", 
                "time_frame": "Wound closure to time hospital discharge order is written or Day 30, whichever is sooner."
            }, 
            {
                "description": "Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.", 
                "measure": "Health economic benefits: Length of stay", 
                "safety_issue": "No", 
                "time_frame": "Wound closure to time hospital discharge order is written or Day 30, whichever is sooner"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963975"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.", 
                "measure": "Incidence of opioid-related adverse events and patient satisfaction with postsurgical analgesia", 
                "safety_issue": "Yes", 
                "time_frame": "Wound closure to time hospital discharge order is written or Day 30, whichever is sooner."
            }, 
            {
                "description": "Responses to one question pertaining to patient satisfaction with postsurgical analgesia and four questions pertaining to postsurgical recovery following hospital discharge.", 
                "measure": "Patient satisfaction with postsurgical analgesia", 
                "safety_issue": "No", 
                "time_frame": "Wound closure to time hospital discharge order is written or Day 30, whichever is sooner."
            }
        ], 
        "source": "Pacira Pharmaceuticals, Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Registrat-Mapi", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pacira Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}